Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Status:
Unknown status
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This research study measures the safety and efficacy of the combination of three drugs that
are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia
(CLL). These drugs are being given together for investigational purposes as the specific
combination of these three drugs has not been approved for treatment of CLL by the FDA.
Phase:
Phase 4
Details
Lead Sponsor:
East Valley Hematology and Oncology Medical Group
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Mena, Raul, M.D. Pharmatech Oncology